Amphastar Pharmaceuticals, Inc.
$22.92
▲
1.04%
2026-04-21 05:17:00
www.amphastar.com
NMS: AMPH
Explore Amphastar Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.02 B
Current Price
$22.92
52W High / Low
$31.26 / $17.03
Stock P/E
10.43
Book Value
$17.28
Dividend Yield
—
ROCE
9.54%
ROE
12.9%
Face Value
—
EPS
$2.03
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,976
Beta
0.91
Debt / Equity
83.16
Current Ratio
4.02
Quick Ratio
2.9
Forward P/E
5.89
Price / Sales
1.3
Enterprise Value
$1.3 B
EV / EBITDA
5.89
EV / Revenue
1.8
Rating
Buy
Target Price
$28
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 2. | Indivior Pharmaceuticals, Inc. | $32.42 | 31.62 | $3.95 B | — | 92.33% | -96.33% | $38 / $8.69 | $-0.78 |
| 3. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 4. | Cronos Group Inc. | $2.76 | — | $1.4 B | — | -1.7% | -0.26% | $4.66 / $2.35 | $2.87 |
| 5. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
| 6. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 7. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 183.1 M | 191.84 M | 174.41 M | 170.53 M | 186.52 M |
| Operating Profit | 35.61 M | 25.32 M | 42.18 M | 37.29 M | 45.14 M |
| Net Profit | 24.43 M | 17.35 M | 31.03 M | 25.29 M | 37.96 M |
| EPS in Rs | 0.54 | 0.38 | 0.68 | 0.56 | 0.84 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 719.89 M | 731.97 M | 644.39 M | 498.99 M |
| Operating Profit | 140.4 M | 205.42 M | 196.99 M | 107.5 M |
| Net Profit | 98.09 M | 159.52 M | 137.54 M | 91.39 M |
| EPS in Rs | 2.16 | 3.52 | 3.03 | 2.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.63 B | 1.58 B | 1.51 B | 741.99 M |
| Total Liabilities | 840.49 M | 845.17 M | 873.49 M | 213.33 M |
| Equity | 788.8 M | 732.3 M | 639.42 M | 528.66 M |
| Current Assets | 636.02 M | 534.07 M | 489.6 M | 378.32 M |
| Current Liabilities | 158.16 M | 173.76 M | 225.41 M | 94.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 156.12 M | 213.39 M | 183.5 M | 89.18 M |
| Investing CF | -70.33 M | -124.93 M | -649.12 M | -32.78 M |
| Financing CF | -67.42 M | -80.95 M | 454.09 M | -26.44 M |
| Free CF | 118.98 M | 172.34 M | 145.34 M | 65.15 M |
| Capex | -37.13 M | -41.04 M | -38.17 M | -24.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13.59% | 29.14% | — | — |
| Earnings Growth % | 15.98% | 50.51% | — | — |
| Profit Margin % | 21.79% | 21.34% | 18.31% | — |
| Operating Margin % | 28.06% | 30.57% | 21.54% | — |
| Gross Margin % | 51.08% | 54.49% | 49.87% | — |
| EBITDA Margin % | 37.89% | 37.29% | 29.29% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.